Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.60 |
| ▸ | CTSK | P43235 | 6/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CTSV | O60911 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.45 |
| ▸ | USP36 | Q9P275 | 1/20 | 0.45 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7984064 | 0.83 | CTSS (0.63) | CTSSCTSKLMNAGAACTSV | |
| SCHEMBL13753318 | 0.83 | CTSS (0.62) | CTSSCTSKLMNAGAACTSV | |
| SCHEMBL108509 | 0.82 | CTSS (0.54) | CTSSCTSKLMNAGAAP2RX7 | |
| SCHEMBL1128084 | 0.82 | LMNA (0.70) | LMNAGAAPTGS1 | |
| SCHEMBL324095 | 0.81 | CTSS (0.57) | CTSSCTSKLMNAGAAP2RX7 | |
| SCHEMBL29542921 | 0.81 | CTSS (0.57) | CTSSCTSKLMNAGAAP2RX7 | |
| SCHEMBL28311763 | 0.80 | CTSS (0.55) | CTSSCTSKLMNAGAAP2RX7 | |
| SCHEMBL18880785 | 0.80 | CTSS (0.56) | CTSSCTSKLMNAGAACTSV | |
| SCHEMBL16093935 | 0.80 | CTSS (0.60) | CTSSCTSKLMNAGAAP2RX7 | |
| SCHEMBL22924535 | 0.80 | CTSS (0.75) | CTSSCTSKCTSVCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | UCL BUSINESS LTD (GB) | 2023-04-25 | — | — | US | disclosed |
| EP-3843844-A1 | COMPOUNDS | UCL Business Ltd (GB) | 2021-07-07 | — | — | EP | disclosed |
| US-20210171475-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2021-06-10 | — | — | US | disclosed |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-12-01 | — | — | US | disclosed |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-12-01 | — | — | US | disclosed |
| WO-2020043866-A1 | COMPOUNDS | UCL BUSINESS LTD (GB) | 2020-03-05 | — | — | WO | disclosed |
| WO-2019195641-A2 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019195641-A2 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-10 | — | — | US | disclosed |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2019-10-10 | — | — | US | disclosed |
| US-8501946-B2 | 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as P2X7 modulators | GLAXO GROUP LIMITED (GB) | 2013-08-06 | — | — | US | disclosed |
| US-20130131340-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | FORMAN BARRY (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2012-06-21 | — | — | US | disclosed |
| EP-2424869-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | Glaxo Group Limited (GB) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| US-20090318693-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | FORMAN BARRY | 2009-12-24 | — | — | US | disclosed |
| US-7544838-B2 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE (US) | 2009-06-09 | — | — | US | disclosed |
| US-20060189825-A1 | Ligands for estrogen related receptors and methods for synthesis of said ligands | CITY OF HOPE | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11634391-B2 | Compounds which are inhibitors of Notum | NOTUM, GOT2, GOT1 | CTSS 1704/4885CTSK 946/4885LMNA 2507/4885 |
| US-20130131340-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | ESRRA, ESRRB, ESR2 | CTSS 2472/4885CTSK 2684/4885LMNA 3802/4885 |
| US-20210171475-A1 | COMPOUNDS | GOT2, GOT1, OAT | CTSS 2282/4885CTSK 917/4885LMNA 1919/4885 |
| US-20060189825-A1 | Ligands for estrogen related receptors and methods for synthesis of said ligands | ESRRA, ESRRB, ESR2 | CTSS 2472/4885CTSK 2684/4885LMNA 3802/4885 |
| US-20190308947-A1 | INHIBITORS OF RHO/MRTF/SRF-MEDIATED GENE TRANSCRIPTION AND METHODS FOR USE OF THE SAME | RHOXF2, BPTF, SREBF1 | CTSS 3355/4885CTSK 3354/4885LMNA 2779/4885 |
| US-10851072-B2 | Inhibitors of Rho/MRTF/SRF-mediated gene transcription and methods for use of the same | RHOXF2, BPTF, SREBF1 | CTSS 3355/4885CTSK 3354/4885LMNA 2779/4885 |
| US-20120157436-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | P2RX7, P2RX6, P2RX3 | CTSS 2738/4885CTSK 1547/4885LMNA 4766/4885 |
| US-20090318693-A1 | LIGANDS FOR ESTROGEN RELATED RECEPTORS AND METHODS FOR SYNTHESIS OF SAID LIGANDS | ESRRA, ESRRB, ESR2 | CTSS 2472/4885CTSK 2684/4885LMNA 3802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.